Interferon-beta: Clinical Trials

24 trials of Interferon-beta, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

14 completed, 4 terminated, 2 active not recruiting, 2 withdrawn. 7 Phase 2, 7 Phase 3, 6 Phase 1, 2 Phase 4, 1 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 27Completed 4, Terminated 2, Withdrawn 1
Phase 37Completed 4, Terminated 2, Recruiting 1
Phase 16Completed 3, Terminated 2, Unknown 1
Phase 42Active not recruiting 1, Withdrawn 1
Not applicable1Completed 1

Follow Interferon-beta: new trials by email Literature Review of Interferon-beta trials Research Report on Interferon-beta

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis
Platform therapies (Dimethyl Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons), Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab) - Relapsing-Remitting Multiple Sclerosis (RRMS), Anti-CD20 Therapy
Phase 3RecruitingUniversity Hospital, Montpellier2502026-06-152026-06-23
A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
Diroximel Fumarate, Alemtuzumab, Fingolimod - Multiple Sclerosis
Active not recruitingBiogen11782021-09-242026-10-15
Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-β1) or Glatiramer Acetate in Relapsing Multiple Sclerosis (RMS)
Placebo, BIIB061, Interferon-beta1 - Relapsing Multiple Sclerosis
Phase 2WithdrawnBiogen2021-06-302023-06-01
Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial
Colchicine, Interferon-Beta, Aspirin - Coronavirus, Severe Acute Respiratory Syndrome
Phase 3CompletedPopulation Health Research Institute66672020-04-212024-01-11
Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS
Early Highly Effective Therapies Group, Escalation Therapies Group - Multiple Sclerosis, Relapsing-Remitting
Phase 4Active not recruitingThe Cleveland Clinic8002019-01-032026-08-31
Mechanism of Action of Ocrelizumab in Multiple Sclerosis
ocrelizumab - Multiple Sclerosis, Immune System Diseases
CompletedUniversity of Chicago302018-02-232025-02-21
A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT
Alemtuzumab GZ402673, Glatiramer acetate, Beta-Interferon - Multiple Sclerosis
Phase 3TerminatedGenzyme, a Sanofi Company162017-10-232026-08-04
Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS)
Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3), Interferon-beta - Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Chronic Progressive
Phase 1UnknownFundació Institut Germans Trias i Pujol162017-07-062023-07-07
COMparison Between All immunoTherapies for Multiple Sclerosis.
Rituximab - Relapsing-remitting Multiple Sclerosis
CompletedKarolinska Institutet35262017-06-022025-04-20
Mesenchymal Stem Cells (MSC) for Ovarian Cancer
MSC-INFβ, Questionnaires - Ovarian Cancer
Phase 1CompletedM.D. Anderson Cancer Center52016-05-162019-07-18
Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma
Avelumab, Laboratory Biomarker Analysis, MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells - Merkel Cell Polyomavirus Infection, Stage IV Merkel Cell Carcinoma AJCC v7
Phase 1 / Phase 2TerminatedFred Hutchinson Cancer Center82015-11-062022-03-22
Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy
Interferon Beta, BIIB017 (Peginterferon beta-1a) - Relapsing Multiple Sclerosis
Phase 4WithdrawnBiogen2014-10-012014-11-17
Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma
Aldesleukin, Laboratory Biomarker Analysis, MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells - Recurrent Merkel Cell Carcinoma, Stage IV Merkel Cell Carcinoma
Phase 1 / Phase 2TerminatedFred Hutchinson Cancer Center42013-02-012017-04-19
Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)
MP-424, RBV(24 weeks), IFN beta(24 weeks) - Chronic Hepatitis C(CHC)
Phase 3CompletedTanabe Pharma Corporation742012-12-012026-01-06
Multiple Sclerosis: Chi3L1 and Treatment Efficacy
Interferon-Beta - Multiple Sclerosis
CompletedCentral Hospital, Nancy, France632012-01-012020-03-09
Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis and Treated With Interferon-beta
Teriflunomide, Placebo (for teriflunomide), Interferon-beta (IFN-beta) - Multiple Sclerosis Relapse
Phase 3TerminatedSanofi5342011-01-012014-06-09
REsPonse to Interferon-Alpha in InterfeRon-β Neutralizing Antibody Positive Multiple Sclerosis Patients
Interferon-beta and human leukocyte Interferon-α - Multiple Sclerosis
Phase 2CompletedMelinda Magyari102010-07-012012-11-30
Safety, Tolerability and Preliminary Efficacy of FP-1201 in ALI and ARDS. Phase I/II
Interferon Beta - Acute Lung Injury, Acute Respiratory Distress Syndrome
Phase 1 / Phase 2CompletedFaron Pharmaceuticals Ltd372009-02-012015-05-27
A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)
Cladribine, Placebo, Interferon-beta (IFN-beta) - Multiple Sclerosis
Phase 2CompletedEMD Serono Research & Development Institute, Inc.1722006-11-302020-10-12
Randomized, Controlled Trial to Test the Efficacy of Interferon Beta in the Treatment of Intermediate Uveitis
Interferon beta, Methotrexate - Uveitis, Intermediate, Macular Edema
Phase 3CompletedHeidelberg University192006-03-012012-12-03

Showing 20 of 24. Sign in to see all of them.

Conditions studied

Multiple Sclerosis (10)  ·  Multiple Sclerosis, Relapsing-Remitting (4)  ·  Carcinoma, Merkel Cell (2)  ·  Acute Lung Injury (1)  ·  Adenoviridae Infections (1)  ·  Adrenoleukodystrophy (1)  ·  Astrocytoma (1)  ·  Brain Neoplasms (1)  ·  COVID-19 (1)  ·  Carcinoma, Ovarian Epithelial (1)  ·  Coronavirus Infections (1)  ·  Glioblastoma (1)  ·  Glioma (1)  ·  Gliosarcoma (1)  ·  Hepatitis C, Chronic (1)

Sponsors

Biogen (4)  ·  Fred Hutchinson Cancer Center (2)  ·  Case Comprehensive Cancer Center (1)  ·  Central Hospital, Nancy, France (1)  ·  EMD Serono Research & Development Institute, Inc. (1)  ·  FDA Office of Orphan Products Development (1)  ·  Faron Pharmaceuticals Ltd (1)  ·  Fundació Institut Germans Trias i Pujol (1)  ·  Genzyme, a Sanofi Company (1)  ·  Heidelberg University (1)  ·  Karolinska Institutet (1)  ·  M.D. Anderson Cancer Center (1)  ·  Melinda Magyari (1)  ·  Population Health Research Institute (1)  ·  Sanofi (1)

Countries

United States (10)  ·  Russia (4)  ·  United Kingdom (4)  ·  France (3)  ·  Italy (3)  ·  Spain (3)  ·  Brazil (2)  ·  Canada (2)  ·  Colombia (2)  ·  Germany (2)  ·  Sweden (2)  ·  Argentina (1)  ·  Australia (1)  ·  Austria (1)  ·  Belgium (1)

Top investigators

Aude Chapuis (2)  ·  Alan Davidson, MD (1)  ·  Alessandra Protti, M.D. (1)  ·  Alexander Binning, MD (1)  ·  Amanda L. Olson, MD (1)  ·  Anders Svenningsson, MD, PhD (1)  ·  Andrea Spissu, M.D. (1)  ·  Angelo Ghezzi, M.D. (1)  ·  Anna Fogdell-Hahn, PhD (1)  ·  Annette Langer-Gould, MD, PhD (1)  ·  Antonio Carolei, M D (1)  ·  Arturo Reggio, Prophessor (1)  ·  Claudio Geda, M.D. (1)

Results publications

PMID 19278300, PMID 24503265, PMID 25877635, PMID 28497489, PMID 30027104, PMID 31501122, PMID 32447743, PMID 34658014, PMID 36228639, PMID 36228641, PMID 37489818, PMID 38744460, PMID 42218617

NIH funding

P30CA015704 (2), 2009 (1), 2015 (1), 2016 (1), 2019 (1), K24CA139052 (1), P30CA043703 (1), R01CA176841 (1)